Johansen Mila Broby, Nielsen Signe Holm, Port Helena, Todberg Tanja, Løvendorf Marianne Bengtson, Skov Lone
Department of Dermatology and Allergy, Copenhagen University Hospital-Herlev and Gentofte, 2900 Hellerup, Denmark.
Department of Clinical Medicine, University of Copenhagen, 2200 Copenhagen N, Denmark.
Int J Mol Sci. 2024 Dec 30;26(1):261. doi: 10.3390/ijms26010261.
Blood-based extracellular matrix (ECM) fragments have been identified as potential pharmacologic biomarkers in spondyloarthritis and diagnostic biomarkers in psoriatic arthritis and psoriasis vulgaris. This study aimed to explore whether ECM fragments can differentiate patients with psoriasis from healthy controls (HC) and determine their potential as biomarkers for response to treatment in psoriasis. The study population included 59 patients with moderate to severe psoriasis, not receiving systemic anti-psoriatic treatment at inclusion, and 52 HC matched by age, sex, and BMI. An EDTA plasma sample was taken from all subjects at inclusion. Nine patients with psoriasis who initiated treatment with adalimumab after inclusion and responded successfully had an additional EDTA plasma sample taken after three to six months. Twelve ECM fragments were measured using validated ELISAs and Immunodiagnostic Systems automated chemiluminescent assays. C4M, indicating collagen IV degradation, PRO-C3, indicating tissue fibrosis, and PRO-C4, indicating epidermal basement membrane turnover showed significantly elevated levels in psoriasis patients compared with HC ( = 0.005, = 0.016, and = 0.018, respectively). Despite successful treatment, adalimumab did not alter C4M, PRO-C3, or PRO-C4 levels. In conclusion, compared with controls, C4M, PRO-C3, and PRO-C4 were elevated in psoriasispatients, but treatment did not modulate these fragments.
血液中的细胞外基质（ECM）片段已被确定为脊柱关节炎的潜在药理学生物标志物以及银屑病关节炎和寻常型银屑病的诊断生物标志物。本研究旨在探讨ECM片段是否能够区分银屑病患者与健康对照（HC），并确定其作为银屑病治疗反应生物标志物的潜力。研究人群包括59例中度至重度银屑病患者，入组时未接受全身性抗银屑病治疗，以及52名年龄、性别和体重指数相匹配的HC。在入组时从所有受试者采集乙二胺四乙酸（EDTA）血浆样本。9例入组后开始使用阿达木单抗治疗且反应良好的银屑病患者在三至六个月后额外采集了EDTA血浆样本。使用经过验证的酶联免疫吸附测定（ELISA）和免疫诊断系统自动化学发光测定法检测了12种ECM片段。与HC相比，表明IV型胶原降解的C4M、表明组织纤维化的PRO-C3以及表明表皮基底膜更新的PRO-C4在银屑病患者中的水平显著升高（分别为 = 0.005、 = 0.016和 = 0.018）。尽管治疗成功，但阿达木单抗并未改变C4M、PRO-C3或PRO-C4的水平。总之，与对照组相比，银屑病患者中C4M、PRO-C3和PRO-C4升高，但治疗并未调节这些片段。
